New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer.
The US Preventive Services Task Force issued a final recommendation on prostate cancer screening, including that men aged 55 to 69 years should make an individual decision on whether or not to be screened.
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy.
An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non–small-cell lung cancer.
The FDA granted approval to the combination of dabrafenib and trametinib for the adjuvant treatment of melanoma, specifically in patients with a BRAF V600E or V600K mutation.
A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances.
An at-home online survey was found to be a reasonably accurate way to collect patient comorbidities prior to a physician visit in patients with prostate cancer.
Alectinib offered significantly improved outcomes over standard chemotherapy in patients with ALK-positive non–small-cell lung cancer who had progressed on crizotinib therapy.
Researchers have developed a new model to help predict the development of breast cancer in women with atypical hyperplasia based on a breast biopsy.
In this video, Dr. Melissa Davis explains how African ancestry may play a role in breast cancer, and ways that genetics might be used to help guide treatment.